Embecta (NASDAQ:EMBC – Get Free Report) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 2.700-2.900 for the period, compared to the consensus estimate of 2.270. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.
Embecta Trading Up 4.3 %
Shares of Embecta stock opened at $14.41 on Tuesday. Embecta has a 12 month low of $9.93 and a 12 month high of $19.79. The stock has a 50 day moving average of $14.33 and a 200 day moving average of $14.04. The firm has a market cap of $831.46 million, a PE ratio of 12.01 and a beta of 0.97.
Embecta Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 18th. Shareholders of record on Friday, December 6th will be given a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a yield of 4.16%. Embecta’s dividend payout ratio (DPR) is presently 50.00%.
About Embecta
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
See Also
- Five stocks we like better than Embecta
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- 3 Stocks That Authorized $1 Billion Stock Buybacks to Boost Value
- What Are Growth Stocks and Investing in Them
- Pure Storage’s GenAI Pods and AI Trends Could Spark Recovery
- Consumer Discretionary Stocks Explained
- Is Seaboard Corporation a Thanksgiving Feast for Investors?
Receive News & Ratings for Embecta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Embecta and related companies with MarketBeat.com's FREE daily email newsletter.
